Neurology

Stryker’s Neuro Division bag is filling nicely with the newly announced acquisition of Surpass Medical, a company with interesting Neuro flow diverter technology in its portfolio.

Data published today in the Headache Society journal Cephalagia shows significant reductions in pain, headache days and migraine-related disability when Peripheral Nerve Stimulation therapy is applied.

St. Jude Medical, Inc. has announced it has received European CE Mark approval of its Eon™ family of neurostimulators for patients with intractable chronic migraine. The range includes the Eon Mini, which St.Jude says is the world’s smallest rechargeable neurostimulator with the longest-lasting battery in its class.

ClearPoint Case Performed in Grenoble, France, the Birthplace of Deep Brain Stimulation Therapy

Registry data published in Neurosurgery suggests Codman’s Enterprise stent-assisted coil embolization system is an effective tool in the occlusion of neurovascular aneurysms with positive outcomes at 21 months.

NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS™) system, called the Monarch™, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older. NeuroSigma’s approval was supported by years of safety and compelling efficacy data generated in clinical trials conducted at the University of California, Los Angeles (UCLA) and the University of Southern California (USC).

German Neurovascular device company Acandis, has announced the CE mark approval of its novel Acclino® 1.9F low profile stent system, designed for use in the interventional neurovascular field as an adjunctive product in treating intracranial aneurysms with coils.

Boston Scientific’s Precisiopn Plus Spinal Cord Stimulator is now CE marked for peripheral nerve stimulation and implantees can receive MRI head-only scans, opening up diagnostic options for clinicians in Europe.

Germans medical device company Cerbomed GmbH has received CE mark clearance for the application of transcutaneous Vagus Nerve Stimulation (t-VNS) in pain relief therapy.

InSightec Receives FDA Approval to Begin Phase I Parkinson’s Trial (via PR Newswire) TIRAT CARMEL, Israel, August 20, 2012 /PRNewswire/ … continue reading “InSightec Receives FDA Approval To Begin Phase I Parkinson’s Trial”

Stryker Neurovascular’s Trevo® Pro Retriever has gained FDA 510(k) market clearance. The Trevo® Pro Retriever outperformed Stryker’s own Merci® Retriever in a clinical study first published in May, showing improved revascularisation compared with the older generation product.

The consequences of our distinct regulatory set-ups is that sometimes study information that drives indications for use one side of the pond is ignored on the other, despite the fact that it may have significant clinical consequences as seems to be the case with Stryker’s Wingspan Neurovascular Stent.

A first patient has been successfully implanted with Medtronic’s DBS device as Functional Neuromodulation Ltd initiates the ADvance Study in the U.S. and Canada to assess the therapy in patients with mild Alzheimer’s disease.

It’s was SNIS 2012 last week, the annual meeting of the Society for Neurointerventional Surgery. Neuro device company Nfocus Neuromedical, Inc., used the occasion to announce positive data from an ongoing clinical study of the company’s Luna Aneurysm Embolization System (AES).

Codman Neurovascular, Inc., has announced the launch of the DELTAMAXX™ Microcoil System, ORBIT GALAXY® G2 Microcoils, and ENVOY DA Guiding Catheter at this year’s SNIS meeting in San Diego.

Nice product, well done for the CE Mark, but should Lazarus Effect be issuing a press release when it’s website’s not even finished? As medtech marketers we’re stumped why anyone would do that.